Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2221-2230 Newer>

The Motley Fool July 27, 2005 W.D. Crotty	Intuitive Surgical's Blowout Quarter The company makes analysts' estimates for the second quarter look anemic. The three analysts following the company will need to update their earnings forecasts for 2005. Still, investors may scoff at the stock's $65.00 price: too high.
The Motley Fool July 27, 2005 Stephen D. Simpson	The Eyes Still Have It Strong demand for laser vision correction has LCA-Vision's investors seeing rainbows.
The Motley Fool July 27, 2005 Stephen D. Simpson	Back Pain for Shorts? Kyphon continues to defy its skeptics. A developer of minimally invasive technology for the spine, the company saw revenue in the second quarter grow 48% as the U.S. business grew about 41% and overseas sales climbed 99%. Investors, take note.
The Motley Fool July 26, 2005 Gardner & Mann	For Shame, Warburg Pincus What transpired as a result of misplaced priorities among these board members who are partners at private equity firm Warburg Pincus is a deal that is substantially underpriced based on Transkaryotic's fundamentals.
The Motley Fool July 26, 2005 Stephen D. Simpson	Lincare Catching Its Breath Growth will be tough for now, but brighter days should lie ahead. Buying and/or holding the healthcare company's stock will be an exercise in patience and confidence in the management team.
BusinessWeek August 1, 2005	The Side Effects of Drugged Crops The Union of Concerned Scientists' Margaret Mellon explains the group's concerns about the dangers genetically altered food poses.
The Motley Fool July 25, 2005 Stephen D. Simpson	Teva Tries to Buy Back the Top Spot $7.4 billion later, Teva Pharmaceuticals is poised to become the largest generics company in the world once again. Investors, take note.
The Motley Fool July 25, 2005 Stephen D. Simpson	Triad Hospitals Looking Healthy The rural hospital operator is in good shape. All the same, the current P/E looks a little robust for a company that will most likely grow in the mid-teens for the next few years.
The Motley Fool July 25, 2005 Charly Travers	Transkaryotic Therapies: What's It Worth? U.K.-based Shire Pharmaceuticals has offered to buy Transkaryotic Therapies for $37 a share. Will shareholders be shortchanged?
BusinessWeek August 1, 2005 Robert Barker	HealthSouth In Rehab Despite scandal, HealthSouth shows potential for investors.
<Older 2221-2230 Newer> Return to current articles.